AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 22 - (NewsRx.com & NewsRx.net) -- Wyeth Pharmaceuticals is informing healthcare providers of important results on combination hormone replacement therapy (HRT) from the Women's Health Initiative Study (WHI).
Results from this trial provide physicians and the public with more definitive information regarding the risks and benefits associated with the long-term use of estrogen plus progestin therapy (or combination HRT).
However, the study did not evaluate the use of combination HRT for the treatment of menopausal symptoms or vaginal atrophy.
"These are valuable new data with significant implications. However, it is also important to recognize the critical role that combination HRT plays in treating the symptoms of menopause, the number one reason that women start therapy," said Victoria Kusiak, MD, vice president, clinical affairs and North American medical director. In a recent survey, doctors report that management of symptoms is a treatment goal for 9 out of 10 new patient starts with combination HRT.
In the WHI trial, the primary endpoints were prevention of coronary heart disease and the incidence of breast cancer. The study found that combination HRT increased the risk of cardiovascular disease (CVD) and, over time, increased the risk of breast cancer. The WHI also found that combination HRT reduced the risk of hip and other fractures and reduced the risk of colon cancer.
The National Institutes of Health (NIH) discontinued the combination HRT arm of the WHI due to the increased risk of invasive breast ...
Source: HighBeam Research, Wyeth informs physicians of WHI findings.(Women's Health Initiative...